A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

Part of paid clinical trials in Lincoln, Nebraska.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07481708
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Enlicitide — DRUG
    Oral administration

Study Details

The goal of this study is to learn what happens to enlicitide (MK-0616) in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of enlicitide and if people tolerate it.

Key Dates

Start date
Mar 23, 2026
Status verified
May 2026
Primary completion
May 18, 2026
Completion
May 25, 2026

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Dose regimen A
    Participants receive enlicitide orally at dose regimen A.
  • Experimental: Dose regimen B
    Participants receive enlicitide orally at dose regimen B.
  • Active Comparator: Dose regimen C
    Participants receive enlicitide orally at dose regimen C.

Primary Outcome Measure

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of enlicitide [ Time Frame: At designated timepoints up to approximately 50 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion ( Site 0001)LincolnNebraska68502-

Find similar trials in Lincoln, NE

By research site
Celerion· Lincoln, NE

Related Studies